rheumatoid arthritis
Etanercept, a       bioengineered soluble receptor fusion protein that blocks tumor necrosis factor       activity, is the first compound in this class to be approved for treatment of       patients with refractory rheumatoid arthritis.
Etanercept, a       bioengineered soluble receptor fusion protein that blocks tumor necrosis factor       activity, is the first compound in this class to be approved for treatment of        @OBJECT$   @PREDICAT$  refractory  @SUBJECT$ .